

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

214517Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: December 11, 2020

TO: Administrative file for NDA 214517

FROM: Latrice Wilson, Senior Regulatory Health Project Manager
Division of Psychiatry, Office of Neuroscience

SUBJECT: Officer/Employee List for NDA 214517

APPLICATION/DRUG: NDA 214517, Hetlioz LQ (tasimelteon) oral suspension

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Alexander, John J
Ampacher, Valerie
Atrakchi, Aisar H
Avila, Amy
Bastings, Eric
Bhattaram, Atul
Birkner, Thomas
Bouie, Teshara
Chelliah, Mariappan
ChithambaramPillai, Venkateswaran
Davis, Michael
Farchione, Tiffany
Fischer, Bernard
Fuller, Barbara
Greeley, George
Harbourt, Kelly
Hausman, Ethan
Holmes, Loretta
Kolejian, Sevan
Mantua, Valentina
Mayrosh, Ruth
Mehta, Mehul U
Nguyen, Phuong B
Papadopoulos, Elektra
Perez, Lawrence
Potter, Andrew

Reissig, Chad J.
Shah, Dhara
Updegraff, Kimberly
Walker, Shetarra
Wang, Joanne
Wu, Ta-Chen
Yang, Peiling
Zhao, Yang (CDER)
Zhuang, Luning (Ada)